12 assets in Inborn Errors Of Metabolism

Therapeutic assets addressing Inborn Errors Of Metabolism, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nexiguran Ziclumeran Inborn Errors Of Metabolism	Intellia Therapeutics	P3	B (60)
Alemtuzumab Inborn Errors Of Metabolism	Paul Szabolcs	P2	CCC (53)
Busulfanum Inborn Errors Of Metabolism	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Cald Hr-D Inborn Errors Of Metabolism	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Clofarabine Inborn Errors Of Metabolism	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Cyclosporin A Inborn Errors Of Metabolism	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Fludarabine Inborn Errors Of Metabolism	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Hpc, Cord Blood Inborn Errors Of Metabolism	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Hydroxyurea Inborn Errors Of Metabolism	Paul Szabolcs	P2	CCC (53)
Melphalan Inborn Errors Of Metabolism	University of California, San Francisco	P2	CCC (53)
Thiotepa Inborn Errors Of Metabolism	University of California, San Francisco	P2	CCC (53)
Duoc-01 Inborn Errors Of Metabolism	Joanne Kurtzberg, MD	P1	CC (43)